BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

Royalty Purchase Agreement

More Like This

BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

(Graphic: Business Wire)

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025